Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 9/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299711 | 0.90 | CYP1A1 (0.42) | SMN1; SMN2ALDH1A1GAALMNACYP1A1 | |
| SCHEMBL14217378 | 0.89 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1HTTGAALMNA | |
| SCHEMBL2304867 | 0.89 | CYP1A1 (0.44) | SMN1; SMN2ALDH1A1HTTGAALMNA | |
| SCHEMBL14708666 | 0.88 | CYP1A1 (0.48) | SMN1; SMN2ALDH1A1HTTGAALMNA | |
| SCHEMBL14238676 | 0.87 | LMNA (0.39) | SMN1; SMN2ALDH1A1GAALMNACYP1A1 | |
| SCHEMBL2302473 | 0.86 | HPGD (0.43) | SMN1; SMN2ALDH1A1HTTPOLBGAA | |
| SCHEMBL2303056 | 0.86 | LMNA (0.56) | SMN1; SMN2ALDH1A1HTTGAALMNA | |
| SCHEMBL2235106 | 0.86 | LMNA (0.56) | SMN1; SMN2ALDH1A1HTTGAALMNA | |
| SCHEMBL2304336 | 0.85 | CYP1A1 (0.45) | SMN1; SMN2ALDH1A1GAALMNACYP1A1 | |
| SCHEMBL12353905 | 0.84 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1HTTPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034888-B2 | Substituted 2-imidazolidones and analogs | UNIVERSITE LAVAL (CA) | 2015-05-19 | — | — | US | disclosed |
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITE LAVAL (CA) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | CCNY, RPS4Y1, TPX2 | SMN1; SMN2 2479/4885ALDH1A1 1937/4885HTT 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.